ABCL Share Price Performance
US$3.49
0.59 (20.34%)
30.2% undervalued intrinsic discount
US$5.00
Fair Value
Price US$3.49
AnalystLowTarget US$5.00
AnalystConsensusTarget US$9.83
AnalystHighTarget US$17.00
Fair ValueUS$5.00
Share Pricen/a
AbCellera Biologics Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 90 Fair Values set on narratives written by author
ABCL Community Narratives
AN
Fair Value US$5 30.2% undervalued intrinsic discount
Clinical And Regulatory Risks Will Limit Upside Despite Potential Recovery
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$9.83 64.5% undervalued intrinsic discount
Phase I Trials And Manufacturing Will Unlock Pipeline Potential
0users have liked this narrative
0users have commented on this narrative
49users have followed this narrative
AN
Fair Value US$17 79.5% undervalued intrinsic discount
AI Integration And Internal Pipeline Will Accelerate Biologics Growth
1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Phase I Trials And Manufacturing Will Unlock Pipeline Potential
Key Takeaways Transition to a clinical-stage biotech and internal programs could drive revenue through milestone fees and royalty payments from new molecules. Integrated clinical manufacturing capabilities will likely boost efficiency and margins, while strong liquidity supports long-term pipeline development.Read more
0users have liked this narrative
0users have commented on this narrative
49users have followed this narrative
AN
US$9.83
64.5% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
51.99% p.a.
Profit Margin
15.51%
Future PE
192.96x
Price in 2028
US$12.23
AI Integration And Internal Pipeline Will Accelerate Biologics Growth
Key Takeaways Innovative trial execution, distinctive product features, and AI-driven antibody discovery position AbCellera to quickly gain market share and attract significant partner interest. Efficient R&D investment, advanced manufacturing, and growing internal pipeline set the stage for improved profitability and outsized long-term royalty and milestone revenues.Read more
1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$17
79.5% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
96.74% p.a.
Profit Margin
14.21%
Future PE
181.01x
Price in 2028
US$20.8
Clinical And Regulatory Risks Will Limit Upside Despite Potential Recovery
Key Takeaways Heavy investment in proprietary technology positions AbCellera for growth, but dependence on clinical milestones and royalties exposes it to significant revenue volatility. Intensified competition, regulatory scrutiny, and alternative therapies may constrain future market share and earnings despite favorable industry trends.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$5
30.2% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
12.44% p.a.
Profit Margin
14.2%
Future PE
284.87x
Price in 2028
US$6.11
Trending Discussion
Recently Updated Narratives
AN
ABCL: Upcoming Clinical Trial Results Will Drive Future Profit Margins Higher
Fair Value: US$9.83 64.5% undervalued intrinsic discount
49 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Clinical And Regulatory Risks Will Limit Upside Despite Potential Recovery
Fair Value: US$5 30.2% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AI Integration And Internal Pipeline Will Accelerate Biologics Growth
Fair Value: US$17 79.5% undervalued intrinsic discount
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
AbCellera Biologics Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.57
- -417.51%
- -485.99%
- 0%
About ABCL
- Founded
- 2012
- Employees
- 596
- CEO
- WebsiteView website
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
